UBS Group’s Xeris Biopharma Holdings XERS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$1.06M Sell
227,865
-635,911
-74% -$2.97M ﹤0.01% 4317
2025
Q1
$4.74M Sell
863,776
-870,715
-50% -$4.78M ﹤0.01% 2999
2024
Q4
$5.88M Buy
1,734,491
+1,451,239
+512% +$4.92M ﹤0.01% 2825
2024
Q3
$807K Buy
283,252
+119,613
+73% +$341K ﹤0.01% 3752
2024
Q2
$368K Sell
163,639
-32,974
-17% -$74.2K ﹤0.01% 4140
2024
Q1
$435K Buy
196,613
+62,201
+46% +$137K ﹤0.01% 4199
2023
Q4
$316K Buy
134,412
+59,972
+81% +$141K ﹤0.01% 4300
2023
Q3
$138K Buy
74,440
+71,083
+2,117% +$132K ﹤0.01% 4519
2023
Q2
$8.8K Sell
3,357
-44,463
-93% -$116K ﹤0.01% 6133
2023
Q1
$77.9K Buy
47,820
+21,707
+83% +$35.4K ﹤0.01% 5047
2022
Q4
$34.7K Buy
26,113
+11,065
+74% +$14.7K ﹤0.01% 5929
2022
Q3
$23K Buy
15,048
+11,991
+392% +$18.3K ﹤0.01% 6128
2022
Q2
$5K Sell
3,057
-47,294
-94% -$77.4K ﹤0.01% 7905
2022
Q1
$129K Buy
50,351
+37,719
+299% +$96.6K ﹤0.01% 4710
2021
Q4
$37K Sell
12,632
-13,900
-52% -$40.7K ﹤0.01% 6089
2021
Q3
$65K Buy
26,532
+20,641
+350% +$50.6K ﹤0.01% 5035
2021
Q2
$24K Sell
5,891
-210,940
-97% -$859K ﹤0.01% 6067
2021
Q1
$978K Buy
216,831
+204,793
+1,701% +$924K ﹤0.01% 3377
2020
Q4
$59K Buy
12,038
+3,959
+49% +$19.4K ﹤0.01% 5058
2020
Q3
$48K Sell
8,079
-7,843
-49% -$46.6K ﹤0.01% 4834
2020
Q2
$42K Sell
15,922
-13,922
-47% -$36.7K ﹤0.01% 5176
2020
Q1
$58K Sell
29,844
-13,769
-32% -$26.8K ﹤0.01% 4830
2019
Q4
$307K Buy
43,613
+15,461
+55% +$109K ﹤0.01% 4288
2019
Q3
$277K Buy
28,152
+14,050
+100% +$138K ﹤0.01% 4137
2019
Q2
$161K Buy
14,102
+4,706
+50% +$53.7K ﹤0.01% 4238
2019
Q1
$94K Hold
9,396
﹤0.01% 4326
2018
Q4
$160K Buy
9,396
+7,072
+304% +$120K ﹤0.01% 4276
2018
Q3
$41K Buy
2,324
+1,858
+399% +$32.8K ﹤0.01% 5409
2018
Q2
$9K Buy
+466
New +$9K ﹤0.01% 6285